NSCLC (Issue 3) | Special Reports

Angiogenesis Biomarkers Show Potential for Predicting PFS and OS in NSCLC

July 31, 2014

Clinical Articles

A handful of angiogenesis biomarkers predicted improved progression-free survival (PFS) and overall survival (OS) in patients with nonsquamous non-small cell lung cancer (NSCLC) treated with bevacizumab.

Update on Next-Generation Therapies for NSCLC

July 31, 2014

Clinical Articles

Treatment for non-small cell lung cancer (NSCLC)—which includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma—has traditionally consisted of surgery, chemotherapy, and radiation therapy.

Adverse Events Associated With CO-1686

July 30, 2014

Clinical Articles

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses adverse events (AEs) associated with CO-1686 for patients with non-small cell lung cancer (NSCLC).

Peer Discussion on Maintenance Therapy in NSCLC

July 30, 2014

Clinical Articles

Some of our top key opinion leaders gathered recently for a discussion on evolving treatment approaches in NSCLC. The following transcript comes from segments that discuss maintenance therapy in detail.

Trials of Anti-PD-L1 in NSCLC Are Well Under Way

July 30, 2014

Clinical Articles

Despite standard chemotherapy and the availability of targeted therapies such as bevacizumab, cetuximab, and tyrosine kinase inhibitors (TKIs) such as erlotinib, afatinib, and crizotinib, survival rates are far from optimal for patients with NSCLC.